EULAR recommendations for the treatment of systemic sclerosis: 2023 update

Objectives: To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. Methods: An international task force was convened in line with EULAR standard operating procedures. A nominal...

ver descrição completa

Detalhes bibliográficos
Autores: Del Galdo, F, Lescoat, A, Conaghan, PG, Bertoldo, E, Colic, J, Santiago, T, Suliman, YA, Matucci-Cerinic, M, Gabrielli, A, Distler, O, Hoffmann-Vold, AM, Castellví, I, Balbir-Gurman, A, Vonk, M, Ananyeva, L, Rednic, S, Tarasova, A, Ostojic, P, Boyadzhieva, V, El Aoufy, K, Farrington, S, Galetti, I, Denton, CP, Kowal-Bielecka, O, Mueller-Ladner, U, Allanore, Y
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p18649
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18649
Access Level:acceso abierto
Palavra-chave:Scleroderma
Systemic
Therapeutics
Connective Tissue Diseases
Pulmonary Fibrosis
Pulmonary Arterial Hypertension
id ES_5b79cf9300ebdb46aaba60a2e8f2d09b
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p18649
network_acronym_str ES
network_name_str España
repository_id_str
spelling EULAR recommendations for the treatment of systemic sclerosis: 2023 updateDel Galdo, FLescoat, AConaghan, PGBertoldo, EColic, JSantiago, TSuliman, YAMatucci-Cerinic, MGabrielli, ADistler, OHoffmann-Vold, AMCastellví, IBalbir-Gurman, AVonk, MAnanyeva, LRednic, STarasova, AOstojic, PBoyadzhieva, VEl Aoufy, KFarrington, SGaletti, IDenton, CPKowal-Bielecka, OMueller-Ladner, UAllanore, YSclerodermaSystemicTherapeuticsConnective Tissue DiseasesPulmonary FibrosisPulmonary Arterial HypertensionObjectives: To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. Methods: An international task force was convened in line with EULAR standard operating procedures. A nominal group technique exercise was performed in two rounds to define questions underpinning a subsequent systematic literature review. The evidence derived was discussed and overarching principles, recommendations and future research agenda were iteratively developed with voting rounds. Results: The task force agreed on 22 recommendations covering 8 clinical/organ domains including Raynaud's phenomenon, digital ulcers, pulmonary arterial hypertension, scleroderma renal crisis, skin fibrosis, interstitial lung disease (ILD), gastrointestinal manifestations and arthritis. Most new recommendations are related to skin fibrosis and ILD. These included novel recommendations for the use of mycophenolate mofetil, nintedanib, rituximab and tocilizumab for the treatment of these crucial disease manifestations. The recommendations also included first-line and second-line interventions, providing increased utility for rheumatology practitioners. Important additions to the future research agenda included consideration of novel interventions for the management of vascular, musculoskeletal and gastrointestinal manifestations and calcinosis, as well as for the local management of digital ulcers. Conclusion: These updated recommendations include the first set of synthetic and biological targeted therapies recommended for key fibrotic manifestations of SSc as well as first-line combination treatment for newly diagnosed pulmonary artery hypertension and prioritise a new research agenda for the coming years.BMJ PUBLISHING GROUP2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18649ANNALS OF THE RHEUMATIC DISEASESISSN: 00034967ISSNe: 14682060reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p186492026-06-14T12:41:47Z
dc.title.none.fl_str_mv EULAR recommendations for the treatment of systemic sclerosis: 2023 update
title EULAR recommendations for the treatment of systemic sclerosis: 2023 update
spellingShingle EULAR recommendations for the treatment of systemic sclerosis: 2023 update
Del Galdo, F
Scleroderma
Systemic
Therapeutics
Connective Tissue Diseases
Pulmonary Fibrosis
Pulmonary Arterial Hypertension
title_short EULAR recommendations for the treatment of systemic sclerosis: 2023 update
title_full EULAR recommendations for the treatment of systemic sclerosis: 2023 update
title_fullStr EULAR recommendations for the treatment of systemic sclerosis: 2023 update
title_full_unstemmed EULAR recommendations for the treatment of systemic sclerosis: 2023 update
title_sort EULAR recommendations for the treatment of systemic sclerosis: 2023 update
dc.creator.none.fl_str_mv Del Galdo, F
Lescoat, A
Conaghan, PG
Bertoldo, E
Colic, J
Santiago, T
Suliman, YA
Matucci-Cerinic, M
Gabrielli, A
Distler, O
Hoffmann-Vold, AM
Castellví, I
Balbir-Gurman, A
Vonk, M
Ananyeva, L
Rednic, S
Tarasova, A
Ostojic, P
Boyadzhieva, V
El Aoufy, K
Farrington, S
Galetti, I
Denton, CP
Kowal-Bielecka, O
Mueller-Ladner, U
Allanore, Y
author Del Galdo, F
author_facet Del Galdo, F
Lescoat, A
Conaghan, PG
Bertoldo, E
Colic, J
Santiago, T
Suliman, YA
Matucci-Cerinic, M
Gabrielli, A
Distler, O
Hoffmann-Vold, AM
Castellví, I
Balbir-Gurman, A
Vonk, M
Ananyeva, L
Rednic, S
Tarasova, A
Ostojic, P
Boyadzhieva, V
El Aoufy, K
Farrington, S
Galetti, I
Denton, CP
Kowal-Bielecka, O
Mueller-Ladner, U
Allanore, Y
author_role author
author2 Lescoat, A
Conaghan, PG
Bertoldo, E
Colic, J
Santiago, T
Suliman, YA
Matucci-Cerinic, M
Gabrielli, A
Distler, O
Hoffmann-Vold, AM
Castellví, I
Balbir-Gurman, A
Vonk, M
Ananyeva, L
Rednic, S
Tarasova, A
Ostojic, P
Boyadzhieva, V
El Aoufy, K
Farrington, S
Galetti, I
Denton, CP
Kowal-Bielecka, O
Mueller-Ladner, U
Allanore, Y
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Scleroderma
Systemic
Therapeutics
Connective Tissue Diseases
Pulmonary Fibrosis
Pulmonary Arterial Hypertension
topic Scleroderma
Systemic
Therapeutics
Connective Tissue Diseases
Pulmonary Fibrosis
Pulmonary Arterial Hypertension
description Objectives: To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. Methods: An international task force was convened in line with EULAR standard operating procedures. A nominal group technique exercise was performed in two rounds to define questions underpinning a subsequent systematic literature review. The evidence derived was discussed and overarching principles, recommendations and future research agenda were iteratively developed with voting rounds. Results: The task force agreed on 22 recommendations covering 8 clinical/organ domains including Raynaud's phenomenon, digital ulcers, pulmonary arterial hypertension, scleroderma renal crisis, skin fibrosis, interstitial lung disease (ILD), gastrointestinal manifestations and arthritis. Most new recommendations are related to skin fibrosis and ILD. These included novel recommendations for the use of mycophenolate mofetil, nintedanib, rituximab and tocilizumab for the treatment of these crucial disease manifestations. The recommendations also included first-line and second-line interventions, providing increased utility for rheumatology practitioners. Important additions to the future research agenda included consideration of novel interventions for the management of vascular, musculoskeletal and gastrointestinal manifestations and calcinosis, as well as for the local management of digital ulcers. Conclusion: These updated recommendations include the first set of synthetic and biological targeted therapies recommended for key fibrotic manifestations of SSc as well as first-line combination treatment for newly diagnosed pulmonary artery hypertension and prioritise a new research agenda for the coming years.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18649
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18649
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv BMJ PUBLISHING GROUP
publisher.none.fl_str_mv BMJ PUBLISHING GROUP
dc.source.none.fl_str_mv ANNALS OF THE RHEUMATIC DISEASES
ISSN: 00034967
ISSNe: 14682060
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408802664611840
score 15,812429

Registos relacionados